# US 2010/0168193 A1 · Therapeutic use of imidazole-5-carboxylic acid derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168193 A1
- Document ID: US20100168193A1
- Status: Published application
- Kind: A1
- Application number: 12/663,183
- Filed: 2008-06-06
- Published: 2010-07-01
- Earliest claimed: 2007-06-07
- Assignees: Shanghai Allist Pharmaceuticals, Inc.
- Inventors: Jianhui Guo
- Web page: https://patentgrep.com/patent/US20100168193A1

## CPC

- C07D 403/10: linked by a carbon chain containing aromatic rings
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention discloses the use of 2-butyl-4-chloro-1-[2′-(1H-tetrazol-5-yl)1,1′-biphenyl-methyl]-imidazole-5-carboxylic acid, 1-[(isopropoxycarbonyl)oxy] methyl ester and the pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of the damage of a target organ caused by hypertension. It particularly discloses the use of this compound in the manufacture of a medicament for the treatment of left ventricular hypertrophy, renal dysfunction, aorta thickening caused by hypertension, which provides an effective drug and method for the treatment of the damage of target organs for hypertension patients.

## Claims

### Claim at position 1

-10. (canceled)

### Claim 11

A method for the treatment of the damage of a target organ caused by hypertension, comprising administering to a subject in need thereof a compound of formula (I) or a pharmaceutically acceptable salt thereof

### Claim 12 (depends on 11)

The method according to claim 11, wherein the compound of formula (I) or the pharmaceutically acceptable salt thereof is administered in the dosage of about 0.5-about 50 mg/kg/day.

### Claim 13 (depends on 11)

The method according to claim 11, wherein the compound of formula (I) or the pharmaceutically acceptable salt thereof is administered in the dosage of about 1-about 20 mg/kg/day.

### Claim 14 (depends on 11)

The method according to claim 11, wherein the compound of formula (I) or the pharmaceutically acceptable salt thereof is administered in the dosage of about >2 mg/kg/day.

### Claim 15 (depends on 11)

The method according to claim 11, wherein the compound of formula (I) or the pharmaceutically acceptable salt thereof is administered in the dosage of about >3 mg/kg/day.

### Claim 16 (depends on 11)

The method according to claim 11, wherein said damage of a target organ comprises the damage of heart, brain, kidney or blood vessel caused by hypertension.

### Claim 17 (depends on 16)

The method according to claim 16, wherein said damage of a target organ comprises left ventricular hypertrophy, stroke, renal cortex atrophy or aorta thickening.

### Claim 18 (depends on 11)

The method according to claim 11, wherein the compound of formula (I) or the pharmaceutically acceptable salt thereof is formulated in a medicament, wherein said medicament comprises about 20 mg-1000 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 19 (depends on 11)

The method according to claim 11, wherein the compound of formula (I) or the pharmaceutically acceptable salt thereof is formulated in a medicament, wherein said medicament comprises about 50-about 500 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 11)

The method according to claim 11, wherein the dosage form of said medicament is an oral dosage form, injection, formulation for sublingual administration, or patch, preferably comprises tablet, capsule, granule, pill, or suspension.

### Claim 21

A method for the treatment of the damage of a target organ caused by hypertension, comprising administering to a subject in need thereof a composition comprising the compound of formula (I) or a pharmaceutically acceptable salt thereof

### Claim 22 (depends on 21)

The method according to claim 21, wherein the content of the compound of formula (I) or the pharmaceutically acceptable salt thereof in the composition is about 20 mg-about 1000 mg.

### Claim 23

A pharmaceutical composition for oral or sublingual administration, which contains about 50 mg-about 1000 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier

### Claim 24 (depends on 23)

The pharmaceutical composition according to the claim 23, wherein the content of the compound of formula (I) or the pharmaceutically acceptable salt thereof in said composition is about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg or about 1000 mg.
